Track Acurx Pharmaceuticals's receivables ($56K) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
The latest receivables for ACXP is $56K as of March 2026. In the prior-year period, the figure was $0. Investors often review this figure alongside Acurx Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.
Over the past year, ACXP's receivables moved from $0 to $56K. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Acurx Pharmaceuticals's operating scale or balance-sheet position.
A receivables figure of $56K for ACXP is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.
After noting ACXP's receivables ($56K), review year-over-year change from $0, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Acurx Pharmaceuticals's receivables against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.